|
|
|
|
|
Olopatadine
drug data and news
Olopatadine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Olopatadine | ||
| Brand Names/Synonyms | Olopatadine; Olopatadine Hydrochloride; Patanol | ||
| Indication | For the treatment of the signs and symptoms of allergic conjunctivitis. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. | ||
| Mechanism Of Action | Olopatadine is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. | ||
| Olopatadine News (When available) |
Kyowa Hakko Profits Decline on Higher R&D Spend but Recurring ... Apr 27, 2006 | ||
| Dosage Forms | LIQUID | ||
| Drug_Category | Anti-allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihistamines; Histamine H1 Antagonists; ATC:S01GX09 | ||
| Absorption | Ophthalmic use of olopatadine usually does not produce measurable plasma concentrations. | ||
| Interactions |
-->Interactions for Olopatadine: No information provided. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C21H23NO3 | ||
| Molecular Weight | 337.412 g/mol | ||
| Smiles String | CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O | ||
| Melting Point | 248 °C | ||
| Water Solubility | Soluble | ||
| State | Solid (white powder) | ||
| LogP/Hphobicity | 3.862 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | The mono-desmethyl and the N -oxide metabolites have been detected at low concentrations in the urine. | ||
| Half Life | 3 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Olopatadine.html http://www.rxlist.com/cgi/generic2/olopat.htm http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/pat1633.shtml | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00310 | ||
| CAS Registry Number | 113806-05-6 | ||
| KEGG Compound ID | C07789 | ||
| PubChem ID | SID:698647 | ||
| PharmGKB ID | PA450698 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2233143 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |